1. Omland T, and White HD: State of the art: blood biomarkers for risk stratification in patients with stable ischemic heart disease. Clin Chem. 2017;63:165–176.
2.Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, Chamberlain AM, Chang AR, Cheng S, Das SR, Delling FN, Djousse L, Elkind MSV, Ferguson JF, Fornage M, Jordan LC, Khan SS, Kissela BM, Knutson KL, Kwan TW, Lackland DT, Lewis TT, Lichtman JH, Longenecker CT, Loop MS, Lutsey PL, Martin SS, Matsushita K, Moran AE, Mussolino ME, O'Flaherty M, Pandey A, Perak AM, Rosamond WD, Roth GA, Sampson UKA, Satou GM, Schroeder EB, Shah SH, Spartano NL, Stokes A, Tirschwell DL, Tsao CW, Turakhia MP, VanWagner LB, Wilkins JT, Wong SS, Virani SS; and American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee: Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. Circulation. 2019;139:e56-e528.
3. Tsimikas S: A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. J Am Coll Cardiol. 2017;69(6):692-711.
4. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, and Nordestgaard BG: Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. 2009;301:2331. 9.
5. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R,
Watkins H, and Farrall M: Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361:2518–2528.
6. Nordestgaard BG, and Langsted A: Lipoprotein(a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. J Lipid Res. 2016;57:1953–1975.
7. Madsen CM, Kamstrup PR, Langsted A, Varbo A, and Nordestgaard BG: Lp(a) (Lipoprotein[a])-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study. Arterioscler Thromb Vasc Biol. 2019 Oct 3:ATVBAHA119312951.
8. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovanen PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgozoglu L, and Tybjaerg-Hansen A: Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 2010;31:2844–2853.
9. Langsted A, Kamstrup PR, and Nordestgaard BG: High lipoprotein(a) and high risk of mortality. Eur Heart J. 2019;40(33):2760-2770.
10. Schmidt K, Noureen A, Kronenberg F, and Utermann G: Structure, function, and genetics of lipoprotein(a). J Lipid Res. 2016;57:1339–1359.
11. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, Kostis JB, and et al: Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA. 2005;294:1799–1809.
12. Mjelva OR, Svingen GFT, Pedersen EKR, Seifert R, Kvaloy JT, Midttun O, Ueland PM, Nordrehaug JE, Nygård O, and Nilsen DWT: Fibrinogen and neopterin is associated with future myocardial infarction and total mortality in patients with stable coronary artery disease. Thromb Haemost. 2018;118:778–790.
13. Ang L, Behnamfar O, Palakodeti S, Lin F, Pourdjabbar A, Patel MP, Reeves RR, and Mahmud E: Elevated baseline serum fibrinogen: effect on 2-yearmajor adverse cardiovascular events following percutaneous coronary intervention. J Am Heart Assoc. 2017;6.
14. Jansen AC, van Aalst-Cohen ES, Tanck MW, Trip MD, Lansberg PJ, Liem AH, van Lennep HW, Sijbrands EJ, and Kastelein JJ: The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patients. J Intern Med. 2004;256:482–490.
15. Schwartz GG, Ballantyne CM, Barter PJ, and et al: Association of lipoprotein(a)with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018;3:164–168.
16. Zhou BY, Sun D, Wang C, Wu NQ, Guo YL, Zhu CG, Gao Y, Liu G, Dong Q, and Li JJ: Plasma Lipoprotein(a) Concentration Is Associated With the Coronary Severity but Not With Events in Stable Coronary Artery Disease Patients: A Chinese Cohort Study. Heart Lung Circ. 2019;28:1009-1017.
17. Konishi H, Miyauchi K, Kasai T, Tsuboi S, Ogita M, Naito R, Sai E, Fukushima Y, Katoh Y, Okai I, Tamura H, Okazaki S, and Daida H: Impact of lipoprotein(a) as residual risk on long-term outcomes in patients after percutaneous coronary intervention. Am J Cardiol. 2015;115:157–160.
18. Jin JL, Cao YX, Zhang HW, Sun D, Hua Q, Li YF, Guo YL, Wu NQ, Zhu CG, Gao Y, Dong QT, Liu HH, Dong Q, and Li JJ: Lipoprotein(a) and Cardiovascular Outcomes in Patients With Coronary Artery Disease and Prediabetes or Diabetes. Diabetes Care. 2019;42:1312-1318.
19. Schwartz GG, Ballantyne CM, Barter PJ, Kallend D, Leiter LA, Leitersdorf E, McMurray JJV, Nicholls SJ, Olsson AG, Shah PK, Tardif JC, and Kittelson J: Association of lipoprotein(a)with risk of recurrent ischemic events following acute coronary syndrome: analysis of the dal-Outcomes Randomized Clinical Trial. JAMA Cardiol. 2018;3:164–168.
20. Lindahl B: Markers of myocardial damage and inflammation in relation to
long-term mortality in unstable coronary artery disease. FRISC Study Group.
Fragmin during Instability in Coronary Artery Disease. N Engl J Med. 2000;343:
1139–1147.
21. Zhang Y, Zhu CG, Guo YL, Xu RX, Li S, Dong Q, and Li JJ: Higher fibrinogen level is independently linked with the presence and severity of new-onset coronary atherosclerosis among Han Chinese population. PLoS One. 2014;9:e113460.
22. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, Moriarty PM, Rader DJ, Remaley AT, Reyes-Soffer G, Santos RD, Thanassoulis G, Witztum JL, Danthi S, Olive M, and Liu L: NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol. 2018;71:177-192.
23. van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, and Stroes ES: Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. Circulation. 2016;134:611-624.
24. Boffa MB, and Koschinsky ML: Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease? J Lipid Res. 2016;57:745-757.
25. Cantin B, Després JP, Lamarche B, Moorjani S, Lupien PJ, Bogaty P, Bergeron J, and Dagenais GR: Association of fibrinogen and lipoprotein(a) as a coronary heart disease risk factor in men (The Quebec Cardiovascular Study). Am J Cardiol. 2002;89:662-666.